HDAC9 and acute myeloid leukemia: Given reports of augmented NK-cell mediated antileukemic activity in AML following pharmacologic NKG2D-ligand induction, we sought to evaluate whether NKG2D-CAR T cell function may be similarly enhanced, particularly in primary AML where NKG2D-ligand expression is frequently detectable at low levels and HDAC-inhibitors and hypomethylating agents have been clinically tested (48).